Targeting multiple myeloma with nanobody-based heavy chain antibodies, bispecific killer cell engagers, chimeric antigen receptors, and nanobody-displaying AAV vectors
Beteiligte Einrichtungen
Abstract
Nanobodies are well suited for constructing biologics due to their high solubility. We generated nanobodies directed against CD38, a tumor marker that is overexpressed by multiple myeloma and other hematological malignancies. We then used these CD38-specific nanobodies to construct heavy chain antibodies, bispecific killer cell engagers (BiKEs), chimeric antigen receptor (CAR)-NK cells, and nanobody-displaying AAV vectors. Here we review the utility of these nanobody-based constructs to specifically and effectively target CD38-expressing myeloma cells. The promising results of our preclinical studies warrant further clinical studies to evaluate the potential of these CD38-specific nanobody-based constructs for treatment of multiple myeloma.
Bibliografische Daten
Originalsprache | Englisch |
---|---|
Aufsatznummer | 1005800 |
ISSN | 1664-3224 |
DOIs | |
Status | Veröffentlicht - 2022 |
Anmerkungen des Dekanats
Copyright © 2022 Hambach, Mann, Bannas and Koch-Nolte.
PubMed | 36405759 |
---|